LY-2835219 Chemical Structure
5 stars, based on 806 reviews
In stock! Order now!
Price of LY-2835219
We offer a substantial discount on larger orders,
please inquire via email@example.com
or Fax: 1-201-884-1288 (USA Fax#)
LY2835219 is orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. CDK4/6 dual inhibitor LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.
Mol. Formula: C27H32F2N8
CAS#: 1231929-97-7 (free base); 1231930-82-7 (mesylate salt)
Storage Conditions: 2ºC to 8 ºC, or -20ºC for 3 years.
Purchase(buy) inhibitor LY-2835219 at Active Biochem
and the United State(U.S.), Germany, Japan, France,United Kingdom(UK),Switzerland, Australia distributors.